Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Impact of Various Combinations of Potentially Immunogenic Therapeutics on the T Cell Response in Acute Myeloid Leukemia

Jochen Greiner, Patrick J Schuler, Hubert Schrezenmeier, Susanne Hofmann, Marlies Götz

Blood (2024) 144 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2024-205110

Published: 2024

Journal Articles

Enhanced Stimulation of Antigen-Specific Immune Responses Against NPM1-Mutated AML

Jochen Marlies Greiner, Vanessa Schneider, Hubert Schrezenmeier, Susanne Hofmann, Marlies Götz

Blood (2021) 138 (Supplement 1): 1292.

https://doi.org/10.1182/blood-2021-146875

Published: 2021

Journal Articles

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, Birgit Michels, Philip Waldhoff, Leopold Sellner, Felix Korell, Susanne Hofmann, Petra Pavel, Anthony D Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2021-152028

Published: 2021

Journal Articles

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Jochen Greiner, MD, Vanessa Schneider, Dr. rer. nat., Hubert Schrezenmeier, Markus Wiesneth, MD, Susanne Hofmann, MD, Marlies Götz

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-134876

Published: 2020

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Bailin He, PhD, Lei Wang, MD, Brigitte Neuber, Anita Schmitt, MD, Niclas Kneisel, PhD, Thomas Hoeger, PhD, Carsten Mueller-Tidow, MD, Michael Schmitt, MD, Susanne Hofmann, MD

Blood (2019) 134 (Supplement_1): 3226.

https://doi.org/10.1182/blood-2019-122833

Published: 2019

Journal Articles

Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy

Jochen Greiner, Vanessa Schneider, Dr. rer. nat., Hubert Schrezenmeier, MD, Markus Wiesneth, MD, Lars Bullinger, MD, Hartmut Döhner, MD, Susanne Hofmann, MD, Marlies Götz

Blood (2018) 132 (Supplement 1): 2734.

https://doi.org/10.1182/blood-2018-99-111458

Published: 2018

Journal Articles

Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI)

Jochen Greiner, Marlies Götz, Michael Schmitt, MD PhD, Hartmut Döhner, MD, Markus Wiesneth, MD, Donald Bunjes, MD, Susanne Hofmann, MD

Blood (2018) 132 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2018-99-111783

Published: 2018

Journal Articles

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Jean-Marc Hoffmann, Lei Wang, Angela Hückelhoven, PhD, Anita Schmitt, MD, Ulrike Gern, Leopold Sellner, MD, Christian Kleist, PhD, Jessica Wenthe, Patrick Wuchter, MD, Maria-Luisa Schubert, MD, Hyeon Joo Yoo, Ming Ni, Susanne Hofmann, MD, Peter Dreger, MD, Anthony D. Ho, MD, Angelica Loskog, PhD, Michael Schmitt, MD

Blood (2016) 128 (22): 3509.

https://doi.org/10.1182/blood.V128.22.3509.3509

Published: 2016

Journal Articles

Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor

Blood (2016) 128 (22): 2519.

https://doi.org/10.1182/blood.V128.22.2519.2519

Published: 2016

Journal Articles

Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition

Jochen Greiner, Marlies Götz, Vanessa Schneider, Hubert Schrezenmeier, Markus Wiesneth, Lars Bullinger, Hartmut Döhner, MD, Susanne Hofmann

Blood (2016) 128 (22): 4054.

https://doi.org/10.1182/blood.V128.22.4054.4054

Published: 2016

Journal Articles

Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome

Verena Wais, Stephan Bohl, Lukas Kündgen, Stephanie von Harsdorf, Katrina Scholl, Richard F. Schlenk, MD, Susanne Hofmann, C. Philipp Maier, Konstanze Döhner, MD, Maria-Veronica Teleanu, MD, Lars Bullinger, MD, Kathrin Drognitz, Jean-Charles Moulin, Martin Binnenhei, Martin Bentz, MD, Hartmut Döhner, MD, Donald Bunjes, MD, Mark Ringhoffer, MD, Florian Kuchenbauer, MD PhD

Blood (2015) 126 (23): 5523.

https://doi.org/10.1182/blood.V126.23.5523.5523

Published: 2015

Journal Articles

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Susanne Hofmann, MD, Marlies Götz, Cornelia Herbst, Vanessa Schneider, Markus Wiesneth, MD, Donald Bunjes, MD, Hartmut Döhner, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 2442.

https://doi.org/10.1182/blood.V124.21.2442.2442

Published: 2014

Journal Articles

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Vanessa Schneider, Lu Zhang, Markus Rojewski, Lars Bullinger, MD PhD, Susanne Hofmann, MD, Marlies Goetz, Konstanze Doehner, MD, Hartmut Doehner, Prof., Christian Buske, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 5783.

https://doi.org/10.1182/blood.V124.21.5783.5783

Published: 2014

Journal Articles

Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)

Susanne Hofmann, MD, Lisa Müller, Stephanie Harsdorf, MD, Christian Langer, MD, Peter Liebisch, MD, Jochen Greiner, MD, Hartmut Döhner, MD, Donald Bunjes, MD

Blood (2014) 124 (21): 1233.

https://doi.org/10.1182/blood.V124.21.1233.1233

Published: 2014

Journal Articles

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Vanessa Schneider, Lars Bullinger, MD, PhD, Lu Zhang, Markus Rojewski, Markus Wiesneth, Susanne Hofmann, Marlies Goetz, Hubert Schrezenmeier, MD, Ulla Botzenhardt, Thomas F.E. Barth, Konstanze Doehner, MD, Hartmut Doehner, MD, Jochen Greiner, MD

Blood (2013) 122 (21): 2624.

https://doi.org/10.1182/blood.V122.21.2624.2624

Published: 2013

Journal Articles

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations ( NPM1 mut )

Jochen Greiner, Vanessa Schneider, Michael Schmitt, Marlies Götz, Konstanze Döhner, Markus Wiesneth, Hartmut Döhner, Susanne Hofmann

Blood (2013) 122 (6): 1087–1088.

https://doi.org/10.1182/blood-2013-04-496844

Published: 2013

Journal Articles

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, MD, Ph.D, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, Jochen Greiner, MD

Blood (2012) 120 (21): 3592.

https://doi.org/10.1182/blood.V120.21.3592.3592

Published: 2012

Journal Articles

Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell responses in patients with acute myeloid leukemia

Jochen Greiner, Yoko Ono, Susanne Hofmann, Anita Schmitt, Elmar Mehring, Marlies Götz, Philippe Guillaume, Konstanze Döhner, Joannis Mytilineos, Hartmut Döhner, Michael Schmitt

Blood (2012) 120 (6): 1282–1289.

https://doi.org/10.1182/blood-2011-11-394395

Published: 2012

Journal Articles

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Jochen Greiner, MD, Yoko Ono, Susanne Hofmann, Vanessa Schneider, Anita Schmitt, Lu Zhang, Elmar Mehring, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, MD, PhD

Blood (2011) 118 (21): 2569.

https://doi.org/10.1182/blood.V118.21.2569.2569

Published: 2011

NARROW

Impact of Various Combinations of Potentially Immunogenic Therapeutics on the T Cell Response in Acute Myeloid Leukemia

Enhanced Stimulation of Antigen-Specific Immune Responses Against NPM1-Mutated AML

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy

Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI)

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor

Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition

Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations ( NPM1 mut )

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell responses in patients with acute myeloid leukemia

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only